Advertisement

Classification of Intraductal Precursor and Proliferative Lesions

  • Helenice Gobbi
Chapter

Abstract

Proliferative epithelial lesions or mammary epithelial hyperplasia comprises a heterogeneous spectrum of alterations confined to the ductal-lobular system. These lesions are divided into two major categories, ductal and lobular, based on cytological and architectural criteria, meaning no specific origin in ducts or lobes. The new Classification of Breast Tumors of the World Health Organization (WHO) 2012 (Table 1) adopted the classic or traditional terminology of intraductal proliferative lesions and did not recommend the nomenclature of “mammary intraductal neoplasia”proposed by Tavassoli. According to WHO, the concept and terminology of intraductal proliferative lesions should be viewed as an evolving process, which may be modified when new molecular and genetic data are incorporated into the classification of these lesions.

Recommended Reading

  1. 1.
    Boulos FI, Dupont WD, Schuyler PA, Sanders ME, Page DL, Fedda FA, Simpson JF. Clinicopathologic characteristics of carcinomas that develop after a biopsy containing columnar cell lesions: evidence against a precursor role. Cancer. 2012;118(9):2372–7. Invasive carcinomas subsequent to previous biopsy with columnar cell lesions occurred in both breasts; they were histologically varied and had no relation to the type of lesion (with or without flat atypia). The authors concluded that these facts speak against a precursor role for columnar cell lesions.CrossRefGoogle Scholar
  2. 2.
    Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM. Breast cancer risk by extent and type of atypical hyperplasia: an update from the Nurses’ Health Studies. Cancer. 2016;122(4):515–20. This study (part of the project that has accompanied American nurses for many years as to several risk factors), evaluated the risk for breast cancer based on the type and number of outbreaks of atypical hyperplasia in the initial biopsyCrossRefGoogle Scholar
  3. 3.
    Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med. 2015;372(1):78–89. Excellent review on morphological, molecular, epidemiological aspects, risk related to different types of lesions and options for clinical management of atypical breast hyperplasiasCrossRefGoogle Scholar
  4. 4.
    King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945–52. Study of clinical-pathological characteristics of cases of lobular carcinoma in situ followed for a long time. A 2% incidence of invasive carcinoma was observed annually – 63% in the ipsilateral breast and of varied histological types. The risk of invasive carcinoma increased with the number of foci of LCIS and reduced with the use of chemoprophylaxisCrossRefGoogle Scholar
  5. 5.
    Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO Classification of Tumours of the Breast. 4th ed. Lyon: IARC; 2012. This is the most recent Classification of Breast Tumors of the World Health Organization and it contains a description of the criteria for histopathological diagnosis, epidemiology, clinical and molecular aspects of the intraductal and precursor proliferative lesions.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Helenice Gobbi
    • 1
  1. 1.PathologyTriâgulo Mineiro Federal UniversityBelo HorizonteBrazil

Personalised recommendations